Schering AG/Berlex Leukine To Enter Phase III For Crohn's In Early 2004
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Berlex’ Leukine is expected to enter Phase III development for moderately to severely active Crohn’s disease in early 2004, but the primary endpoint to be used is still being negotiated with FDA, the Schering AG subsidiary said Oct. 14.
You may also be interested in...
Schering AG To Continue Leukine Development In Wake Of Phase III Crohn’s Failure
Schering AG will continue clinical development of Leukine for Crohn's disease despite disappointing results from a Phase III induction trial
Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims
Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.
Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims
Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.